A detailed history of Private Capital Group, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Private Capital Group, LLC holds 176 shares of DNLI stock, worth $3,627. This represents 0.0% of its overall portfolio holdings.

Number of Shares
176
Previous 192 8.33%
Holding current value
$3,627
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 28, 2022

SELL
$20.88 - $35.19 $334 - $563
-16 Reduced 8.33%
176 $5,000
Q1 2022

Apr 21, 2022

BUY
$29.0 - $47.27 $1,740 - $2,836
60 Added 45.45%
192 $6,000
Q4 2021

Jan 24, 2022

SELL
$42.59 - $55.02 $7,112 - $9,188
-167 Reduced 55.85%
132 $6,000
Q3 2021

Oct 13, 2021

BUY
$48.48 - $78.23 $13,525 - $21,826
279 Added 1395.0%
299 $15,000
Q2 2021

Jul 26, 2021

BUY
$50.3 - $78.44 $1,006 - $1,568
20 New
20 $2,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.77B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Private Capital Group, LLC Portfolio

Follow Private Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Capital Group, LLC with notifications on news.